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A system for quality-of-life diagnosis and therapy (QoL system) was implemented for breast cancer patients. The system fulfilled the
criteria for complex interventions (Medical Research Council). Following theory and modeling, this study contains the exploratory trial
as a next step before the randomised clinical trial (RCT) answering three questions: (1) Are there differences between
implementation sample and general population? (2) Which amount and type of disagreement exist between patient and coordinating
practitioners (CPs) in assessed global QoL? (3) Are there empirical reasons for a cutoff of 50 points discriminating between healthy
and diseased QoL? Implementation was successful: 74% of CPs worked along the care pathway. However, CPs showed preferences
for selecting patients with lower age and UICC prognostic staging. Patients and CPs disagreed considerably in values of global QoL,
despite education in QoL assessment by outreach visits, opinion leaders and CME: Zero values of QoL were only expressed by
patients. Finally, the cutoff of 50 points was supported by the relationship between QoL in single items and global QoL: no patients
with values above 50 dropped global QoL below 50, but values below 50 and especially at 0 points in single items, induced a dramatic
fall of global QoL down to below 50. The exploratory trial was important for defining the complex intervention in the definitive RCT:
control for age and prognostic stage grading, support for a QoL unit combining patient’s and CP’s assessment of QoL and support for
the 50-point cutoff criterion between healthy and diseased QoL.
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Bio-psycho-social medicine as an integrated approach has become
a paradigm in western societies to understand illness (White, 2005)
and achieve more complete and effective treatment (Wulff and
Gotzsche, 2000; Gimmler et al, 2002). It is, however, complicated to
get evidence for the ‘active ingredients’ (MRC Health Services and
Public Health Research Board, 2000) of such therapeutic regimens,
particularly when the outcome is not just survival, but relates to
patient-reported end points such as quality of life (QoL) (Lorenz
and Koller, 2002). Delivering the multifaceted ingredients of
bio-psycho-social medicine requires complex structures of care,
which have to be set up through systematic implementation
strategies (Klinkhammer-Schalke et al, 2008).
The Medical Research Council (MRC) has termed such
integrated approaches as ‘complex interventions’ (MRC Health
Services and Public Health Research Board, 2000): they differ from
drug vs placebo evaluations in classical randomised trials.
Complex interventions are defined as those in which it is difficult
to characterise precisely the ‘active ingredients’ of intervention and
how they relate to each other. Studies must clarify these
ingredients and relationships before the definitive randomised
trial is conducted. MRC proposed a new procedure for introducing
and evaluating complex clinical interventions including five
phases: theory, modeling, exploratory trial, definitive randomised
trial and long-term implementation. Each phase needs separate
studies and study reports.
The present project introduces and evaluates a system of
diagnosis and therapy of impaired QoL in cancer patients (QoL Received 16 April 2008; accepted 10 June 2008
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ssystem) and adopted the MRC complex intervention approach.
The first paper summarised the conceptual basis underlying the
project (preclinical phase) and modelling (phase 1 of the MRC
scheme, Table 1 (Klinkhammer-Schalke et al, 2008)).
The second paper addresses phase 2, the exploratory trial.
The goals of this trial were twofold: to introduce the concept of
QoL to coordinating practitioners (CPs) in an epidemiologically
defined region (implementation), and to generate data that allow
to fine-tune the study protocol for a subsequent randomised
clinical trial (RCT), answering three questions:
(1) Did the CPs, during implementation, select a sample of
patients, which was different from the general population?
Were age and prognosis prominent factors for inclusion or
exclusion?
(2) To what extent and how specifically did patients’ self-reports
and doctors’ judgements disagree about QoL?
(3) Are there empirical reasons supporting the 50-point cutoff
criterion in the QoL profile to discriminate between healthy
and diseased QoL?
PATIENTS AND METHODS
Study design
According to small area analysis (Wennberg and Gittelson, 1973), a
defined area in Bavaria was selected for implementing and
evaluating the QoL system in breast cancer patients. Within the
service area of the Tumor Center Regensburg it comprised, namely
the urban county of Regensburg and the rural county of Amberg,
in total 500000 inhabitants. The project started with setting up the
infrastructure and physician training in QoL methodology in
August 2002. Patient recruitment started in December 2002 and
was completed in December 2004.
Study participants
The study included 170 patients with primary breast cancer, 10
clinicians (two clinicians from each of the five hospitals in the two
areas), 38 CPs, 12 opinion leaders (i.e., influential physicians in the
region, who are respected and were selected by the CPs) and
75 professional therapists providing the QoL therapeutic options,
and the QoL unit with five experts, including two study coordi-
nators and two data managers. The interaction and the relative
responsibilities of these individuals were determined in a care
pathway (Klinkhammer-Schalke et al, 2008) (Table 1).
Main patient inclusion criteria were diagnosis of primary breast
cancer and informed consent to participate in the study. The study
protocol was approved by the ethics committee of the University of
Regensburg. No restrictions were made regarding the date of the
breast cancer diagnosis or comorbidity, and there was no upper
age limit. However, patients were excluded if they were less than 18
years, unwilling to participate in the study, or unable to self-
complete the German version of the questionnaire because
of their mental or physical condition or poor command of the
German language.
Coordinating practitioners (CPs) were defined as those who
cared for breast cancer patients before and after hospital stay. They
were either gynaecologists or oncologists, or family doctors. CPs
were eligible for the project if they gave their informed consent,
had at least a moderate routine of caring for breast cancer patients
(at least three patients in the years 1999–2001), and agreed to
participate in the multifaceted implementation procedure includ-
ing outreach visits, opinion leaders and continuing medical
education in a quality circle. CPs were expected to recruit three
to six patients for the study.
Professional therapists were those who provided QoL-enhancing
therapies such as pain therapy, physiotherapy and lymphatic
drainage, sports activities and nutrition counseling or social
counseling (Table 1). Their professional background required
specific training in the area of expertise. Professional therapists
participated in quality circles of the Tumor Center Regensburg,
that provided regular trainings using PDCA cycles (PDCA¼plan,
do, check and act) (Klinkhammer-Schalke et al, 2008).
QoL profile and expert report
The patient filled out QoL questionnaires (EORTC QLQ–C 30,
version 2.0, plus the breast cancer module QLQ–BR 23) in their
doctor’s practice. Concurrently, the doctor filled out a health status
form that included diagnostic, therapeutic and social information
and a judgement of patient’s QoL (Table 1). Both forms were sent
to the QoL unit. Patients’ QoL responses were transformed into a
QoL profile (Figure 1) using a computerised QoL visualisation
programme (Middeke et al, 2004). This profile was handed out to
the experts in the QoL unit who independently formulated QoL
diagnosis and treatment recommendations. These individual
statements were discussed weekly in consensus meetings of the
experts resulting in a group decision expert report. It was sent to
the CP caring for the patient. It was ultimately the CP’s choice to
follow the recommendation, to initiate proper treatment by him/
herself or to refer the patient to a professional therapist.
Data management and statistical analysis
Patients’ QoL questionnaire and doctors’ health status question-
naire were collected as paper copies. Data were stored in a
Microsoft ACCESS (version 2003) database. The QoL profile was
produced using a specifically designed QoL-profiler programme
(Middeke et al, 2004).
The statistical analyses of this implementation trial were
primarily descriptive, using counts, percentages, means and
standard deviations, medians and interquartile ranges, and 95%
Table 1 Conceptual, methodological and practical prerequisites of the
QoL system (Klinkhammer-Schalke et al, 2008)
Three component
outcome model
Posits three components to assess a patient’s ‘true’ end
point: (1) objective (e.g., survival); (2) experiential
(e.g., mood); and (3) a judgement of clinical relevance,
(i.e., which end point is most important)
Threshold value On a scale from 0 (very bad) to 100 (very good) a value
below 50 is regarded as ‘diseased’, because this implies
‘quite a bit’ or ‘very much’ symptom appraisal on the
corresponding item.
Quality of life profile Contains 10 QoL dimensions (derived from EORTC-
QLQ-C30+BR23), all scores uniformly scaled from 0 to
100 and displayed in vertical. The graphic presentation
allows to spot QoL impairments at a glance.
Health status form Includes basic information regarding clinical (e.g., tumour
stage) and selected non-clinical variables (e.g., co-fatalities)
and doctor’s overall judgement of patient’s QoL at the
time patients report on their QoL.
Expert report Five experts from different disciplines (medicine,
psychology) individually diagnosed QoL profiles and
the concurrent health status forms, and merged their
perspectives into one single report that is structured
(1) findings, (2) interpretation, and (3) therapeutic
recommendation.
Care pathway Describes the logical chain of the various elements of
primary and follow-up care according to current guidelines,
supplemented by QoL assessments and interventions at
designated time points.
Quality of life
enhancing treatment
options
Evidence suggests that the following treatment options
have QoL enhancing properties: physiotherapy and
lymphatic drainage, pain therapy, psychotherapy, nutrition
counseling and physical fitness, social rehabilitation.
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sconfidence intervals. Patient–doctor agreement was calculated
using Spearman r correlation, interrater correlation coefficient
(Shrout and Ford, 1979), and Bland–Altman plots (Bland and
Altman, 1986). Group differences were calculated using the w
2-test,
t-test, or Wilcoxon test where appropriate. All analyses were
performed using SPSS for Windows, version 15.0.
RESULTS
Did the coordinating practitioner select a sample of
patients that was different from general population?
Were age and prognosis prominent factors for
inclusion or exclusion?
Key indicators for a successful implementation were the number of
patients recruited by CPs and whether the sample was representa-
tive of the population of interest. Twenty-eight of 38 CPs were
active in patient recruitment; this 74% compliance was satisfactory
when compared with the 40% adherence rate in clinical guideline
implementation (Margolis and Cretin, 1999). The majority of
CPs recruited 3–6 patients, the median being 3. There were two
outliers with 23 and 46 recruited patients, respectively.
We analysed the characteristics of the selected sample of
patients (n¼170) to identify representativeness in comparison
to the population of breast cancer patients in the area investigated
between January 2003 and June 2004 (N¼509). This was possible
because of complete documentation of breast cancer patients from
1992 on at the regional Tumor Center. The characteristics of the
patients selected by the CPs were remarkable (Table 2). The small
number of patients receiving chemo- and radiotherapy at the
time of the investigation was because of the timing of patient
enrollment: 75 patients were included within the first month after
surgery and only 20 patients in the first year thereafter.
More importantly, there were differences between implementa-
tion sample and regional population regarding age. The frequency
distribution was bell-shaped in the regional population, but
skewed in the implementation sample, with patients missing
above the age of 70 years (Figure 2). This became even clearer
when proportions were compared. In the implementation sample
only 18 out of 170 patients were X70 years of age (11%; C.I. 6.8–
16.1%), whereas in the regional population this proportion was
almost three times larger, 137 out of 509 (27%, C.I. 22.9–30.6).
Comparisons were drawn with a historic cohort on primary
breast cancer therapy in six regions of Germany, which was
published in 2002 and comprised a sample of N¼8661 (Engel et al,
2002). The proportion of patients aged X70 years was 2425 out of
8661 (27.9%, C.I. 27.1–29.0), almost identical with the regional
population.
The second attribute, which differed between implementation
sample and population, was the prognostic stage (UICC; Figure 3).
The CPs recruited a higher proportion of patients with the
relatively favourable tumour stages 1 and 2, 87% of the cases, as
compared with the 78% prevalence in the regional population
(global w
2-test for all 5 stages: 14.7, d.f. 4, Po0.01), but the picture
was more complex. The CPs selected fewer patients with
carcinoma in situ, but more patients in the palliative group (for
significances see legend in Figure 3).
To what extent did patients’ self-reports and doctors’
judgements disagree?
It is well known that doctors and patients (Koller et al, 1996) show
poor overlap in their assessment and judgement of clinical features.
Patient’s assessment Doctor’s assessment
Global Quality of Life
Somatic
Physical functioning
Role functioning
Arm symptoms
Body image
Pain
Emotion
Fatigue
Psychological
Concentration,
remembering
Social
Family life,
social encounters Very bad
Breakdown in global quality of life and conspicuousness in arm
symptoms, pain and emotion.
Patient is relatively young and shows bad  coping, but is shortly after
surgery.
Very good
Experts' report:
Findings:
Interpretation:
Recommendation: Lymph drainage and pain therapy, consider psychooncological support, 
if emotional problem persist.
Figure 1 QoL profile and experts’ report produced from the EORTC questionnaire by the patient and health status questionnaire by the doctor in the
QoL unit and sent to the coordinating practitioner of the patient implemented in QoL diagnosis and therapy. Example of the largest difference between
patient’s and clinician’s assessment of global QoL in 170 patients. Female patient with primary breast cancer, no. 170 in the series, 1 month after BCT with
axillary lymph adenectomy, 44 years, married, two children. Prognostic classification T1c, N0, M0, G2, ER pos/PR pos, HER2neu neg. Cutoff level:
50 points (grey bar). For further details of the QoL system see reference Klinkhammer-Schalke et al, 2008.
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sThe more important question here was the extent and quality of
disagreement after patients and doctors had been made familiar with
the topic of QoL through an extensive implementation.
The most simple and often found method (Engel et al, 2002) for
analysing differences is collapsing the individual data points into
QoL scores and comparing their means. In our case, patient-
reported global QoL was 66.7 (50.0–77.1) points (median and
interquartile range), mean 61.5 and standard deviation 23.2,
significantly lower than doctors’ judgement of patients’ global
QoL, 75.0 (58.3–83.3), respectively, mean 71.0 and s.d. 18.8,
nonparametric Wilcoxon test for paired data: Po0.001. To put this
result into perspective, comparisons were drawn to the German
Cancer Field Study (Kerr et al, 2003) and the reference values of a
non-patient German population (Schwarz and Hinz, 2001). 63.7
and 69.2 points (means) for global QoL were very similar to our
findings.
The relationship between patient-reported global QoL and
doctors’ judgement were analysed in more detail using various
correlational/regressional methods.
There was significant correlation (Spearman r 0.43, Po0.001),
but the single values were scattered all over the graph (Figure 4A).
One exception occurred: very bad values (below 25 points) for
global QoL were not assessed by the carefully trained CPs. The case
with the strongest disagreement between patient and CP is marked
in the lower right corner of Figure 4A:
The patient reported the least favourable overall response (0),
whereas doctor’s judgement was as high as 83 score points. The
QoL profile (Figure 1), demonstrated, in addition to zero global
QoL, o50 score point impairments in three specific dimensions:
arm symptoms, pain, and emotion.
Doctors presumed that prognosis and QoL were interrelated.
This became apparent in a correlation between doctors’ judge-
ments of patient global QoL and objective UICC stage, Spearman r
of  0.28, Po0.01 (n¼147).
However, this was not true when comparing patient-reported
global QoL with the UICC prognostic stage (Figure 4B), Spearman
r of 0.006, P¼0.94 (n¼148). Two-thirds of patients with UICC
stage IV expressed normal global QoL. One patient scored even a
maximum 100 global QoL score points. In contrast, almost half of
the UICC I patients (most of whom are expected to survive)
demonstrated QoL p50 points (left part of Figure 4B).
The correlation coefficient, however, is just an indicator of a
linear relationship, but not one of agreement (in the sense that two
judgements are identical). Reliability analysis was performed to
answer this question using the intraclass correlation coefficient
(Shrout and Ford, 1979) and Cicchetti and Sparrow’s (1981)
judgement of o0.4, 0.4–0.59, 0.6–0.74 and X0.75 as poor, fair,
good and excellent. In the sample of 158 patients the intraclass
correlation coefficient was 0.54 (95% C.I. 0.37–0.66), correspond-
ing only to fair reliability.
To elucidate the clinical relevance of disagreement between the
judgement of patient and corresponding CP, a Bland-Altman
diagram was plotted (Figure 5) (Bland and Altman, 1986). It
demonstrated a considerable lack of agreement. First, on average,
patient QoL scores were lower than doctors’ estimates (mean
difference¼9.4 score points). Second, data points were scattered
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Figure 2 Age distribution of patients with breast cancer in the study
region as documented by the tumour centre and that of patients selected
by the coordinating practitioners during implementation. Histograms of the
two groups (January 2003 until June 2004).
Table 2 Characteristics of the patients in the implementation sample
(n¼170)
Attributes of the patients Numbers and rates
Age (years, x ˜ (range)) (n¼170) 58 (34–86)
Time after primary treatment (months,
x ˜ (i.q. range and range)) (n¼168)
4 (1–31) and (1–202)
Prognostic stage grouping (UICC, n¼153)
UICC 0 4
UICC I 65
UICC II (II a and b combined) 64
UICC III (III a, b, c combined) 9
UICC IV 11
Receptor status
Estrogen positive/negative 137/23
Progesterone positive/negative 126/34
Her2neu positive/negative 35/82
Present phase of therapy
Postoperative, BCT/mastectomy 100/63
Chemotherapy positive/negative 20/148
Radiotherapy positive/negative 7/161
Endocrine therapy positive/negative 61/107
Professional status
Housewife 46
Working outside the home 100
On pension 24
Family status
Married/not married 122/40
Children/no children 137/28
Numbers less than 170 in the sample are due to missing values.
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Figure 3 Prognostic stage (UICC) of the patients in the implementation
sample and the regional population. Missing values in sample n¼17, in
population n¼64, global test: w
2¼14.689 (d.f. 4), Po0.005; single tests:
UICC 0: w
2¼3.913 (d.f. 1), Po0.05, UICC III: w
2¼9.296 (d.f. 1) Po0.005,
all other tests not significant.
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sacross the whole diagram. Hence one judgement could not be
replaced by the other (Bland and Altman, 1986), whereas
judgements of extreme values of QoL (o40 and 480 score
points) remained within the levels of agreement (mean±2 s.d.), in-
between values (440 and o80 score points) showed much more
discrepancies, often outside the levels of agreement. These
deviations by far exceeded that commonly agreed upon criterion
of minimal–clinically–relevant difference of 10 score points
(Osoba et al, 1998; Norman et al, 2003).
One aspect of clinical relevance that had not yet been touched by
the previous methods was the degree of relative negativity. In other
words, how often was the patient or the doctor more negative in
judging global QoL? A sensitivity analysis, using five value ranges
of patient-reported QoL (0, o25, o50, X50, 0–100) as anchors,
was performed (Figure 6). In the normal range (X50 points)
relative negativity followed largely chance distribution, but below
50 points relative negativity was on the patient’s side, that is,
patients’ self-reports are much more negative than doctors’
judgements. Doctors failed completely to recognise very bad QoL
(o25 and 0 points).
Are there empirical reasons supporting the 50-point cutoff
criterion in the QoL profile to discriminate between
healthy and diseased QoL?
Conceptual reasons (Koller and Lorenz, 2002) led us to suggest a
50-point criterion in the QoL profile to discriminate between
‘healthy’ and ‘diseased’ states in all listed 10 dimensions.
Interpretation and reliable threshold levels are major points of
discussion. In the literature there is no consensus on a gold
100
80
60
40
20
0
0 2 04 06 08 0 1 0 0
G
l
o
b
a
l
 
Q
o
L
 
(
p
a
t
i
e
n
t
)
 
(
p
o
i
n
t
s
 
i
n
 
s
c
a
l
e
 
o
f
 
0
–
1
0
0
)
100
80
60
40
20
0
G
l
o
b
a
l
 
Q
o
L
 
(
p
a
t
i
e
n
t
)
 
(
p
o
i
n
t
s
 
i
n
 
s
c
a
l
e
 
o
f
 
0
–
1
0
0
)
Global QoL (CP) (points in scale of 0–100)
0 I IIa IIb IIIa IIIb IIIc IV
Prognostic stage grouping (UICC)
Figure 4 Relationship between assessment of global QoL by the patient herself and by her CP. Comparison with the UICC grouping. For conditions of
assessment see Patients and methods. For UICC grading a linear scale was assumed for the statistical model. (A) y¼22þ0.56x; Spearman r¼0.43;
P(2a)o0.01; n¼158; } case with the strongest disagreement, for details of this patient see Figure 1. (B) y¼64 0.48x; Spearman r¼0.006; p(2a)¼n.s.;
n¼148; &   case with the worst prognosis, but maximum global QoL.
Mean + 2s.d. = 35.1
Mean = –9.4
Mean – 2s.d. = –53.9
60
30
0
–30
–60
–90
0 2 04 06 08 0 1 0 0
Average of global QoL assessed by patient and CP
(points in scale of 0–100)
D
i
f
f
e
r
e
n
c
e
 
i
n
 
g
l
o
b
a
l
 
Q
o
L
 
a
s
s
e
s
s
e
d
 
b
y
 
p
a
t
i
e
n
t
 
a
n
d
 
C
P
(
p
o
i
n
t
s
 
i
n
 
s
c
a
l
e
 
o
f
 
0
–
1
0
0
)
Figure 5 Bland–Altman plot (Bland and Altman, 1986) for agreement
analysis between the judgement of the patient and her CP about global
QoL. Differences and mean values were calculated for each of the patients.
Limits of agreement are the upper and the lower two s.d. values calculated
for normal distribution of all differences in the sample (n¼158).
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sstandard (FDA, 2006); but are there empirical reasons to support
the 50-point criterion?
One way of looking at the boundary conditions of decline in
global QoL is to investigate threshold levels of specific QoL
dimensions and their relations to global QoL (Figure 7). If all
values for specific QoL dimensions, such as pain or arm symptoms
were 460 or 450 (and therefore in the satisfactory range)
(Schwarz and Hinz, 2001), global QoL in none of the patients fell
below 50 (left side of Figure 7). However, the turning point was
o50 thus supporting the 50 score points as the cutoff between
‘healthy and diseased’. Figure 7 very clearly showed the intimate
relations between QoL in single, specific dimensions and global
QoL; the negative extreme, zero value in any specific dimension
was associated with a dramatic decline in global QoL (right part of
Figure 7).
This effect became even more apparent in Figure 8A and B: if no
zero-point breakdown was observed in the QoL profile, the vast
majority of global QoL scores was in the ‘normal’ 450 score point
range and only 13 of 129 (10%) patients showed a global QoLo50
(Figure 8A). If, however, at least one single zero-point breakdown
was detected, 15 of 29 (52%) patients showed a global QoLo50
(Figure 8B).
DISCUSSION
Data analysis of the exploratory trial was guided by three
questions.
(1) The selection of patients for implementation by their
CPs
It uncovered age discrimination (‘patients over 70 years do not
need treatment of their (bad) quality of life!’). Other reasons for
the biased selection were proposed by the CPs in this study. They
claimed that they see more often younger patients in daily practice
than older ones and have therefore selected them just by chance.
Older patients are less mobile, and are more likely to have called a
CP to their home. Furthermore, many patients came to the CPs
early after surgery. This was not the case with older patients
(Watermann et al, 2005). Finally, younger patients often demon-
strated more dramatic cases with many social problems and were
therefore selected by the CPs for the QoL study. As the German
study demonstrated (Watermann et al, 2005), older patients (470
years) received less chemo- and radiotherapy than younger
patients. This has consequences for randomised trials: selection
bias must be controlled as older patients are underrepresented in
clinical trials and are at risk for higher mortality rates. These
problems are now becoming widely recognised and the EORTC has
installed a Task Force for the Elderly (Wildiers et al, 2007).
Elderly patients should not be excluded from QoL therapy; quite
to the contrary they might be the age group that may mostly profit.
Therefore, the study protocol for the randomised trial took special
care not to exclude elderly patients (Koller et al, 2006).
(2) Disagreement between the patients’ and doctors’
assessment and judgement of quality of life
This question is not new in QoL research, but remained a matter of
persisting concern (Koller et al, 1996; Sneeuw and Aaronson, 2002;
Groenvold et al, 2007). Factors responsible for the disagreement
include concreteness, visibility, subjectivity, living arrangements,
caring function, close proximity to the patient (Sneeuw and
Aaronson, 2002), and also employment of well-validated QoL
questionnaires, longitudinal design and sufficient sample sizes
(small: no50, definitive: n4100). The present exploratory trial
differs from those approaches in several ways:
  The situation was routine clinical care (Klinkhammer-Schalke
et al, 2008), not a scientific setting with its well-known
reductionism.
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judge patient global QoL. Doctors gave their judgement at the
very end of the health status form that included all relevant
information on patients’ current status of health and treatment
and also psychosocial co-fatalities (Troidl et al, 1998).
  The doctors were trained in QoL assessment during the
implementation procedure, especially by outreach visits
(Klinkhammer-Schalke et al, 2008). Hence they knew about
the subject and what to do.
  Finally, the influence of relatives on QoL (social stigma (Koller
et al, 1996)) was avoided by patients filling out the ques-
tionnaires in a separate room of the CPs. Despite those
restrictions against bias, the disagreement remained very large.
The consequences for the subsequent randomised trial were:
  Instead of debating who is right, the patient or the doctor, both
sides of the outcome model (Lorenz and Koller, 2002) have to be
integrated (Table 1). This is achieved by the multidisciplinary
expert team in the QoL system.
  The expert report, however, has to give precise recommenda-
tions to the CPs (Figure 1).
  A telephone-based recall system was installed to check whether
the CP has used the expert report in his/her decision.
(3) 50-point cutoff criterion for healthy vs diseased QoL
For two reasons (Koller and Lorenz, 2002) a score value of 50 in a
range from 0¼very bad to 100¼very good was regarded as the
threshold level for medical intervention (iatrotropy):
(1) The EORTC QoL questionnaire items tap into patients’ degree
of impairment and answers can be given on Likert scales of 1–
4( 1¼not at all, 4¼very much so). Responses of the patient to
a symptom item (e.g., pain) can be easily dichotomised with 1
and 2 as the ‘good’ side and 3 and 4 as the ‘bad’ side. Hence,
face validity is in favour of the 50-point cutoff criterion (Koller
and Lorenz, 2002).
(2) According to theories on adaptation level and social
comparison (Festinger, 1954) persons generally try to perform
slightly better than average. Values under average (50 points)
are undesirable; the goal of therapy is to bring patients to over
50 points. Indeed, the normal values for global QoL in the
German population were found between 60 and 80 points
(Schwarz and Hinz, 2001). Also for pain therapy in a surgery
clinic, 50 points on a visual analogue scale from 0 to 100 were
taken as the threshold value for intervention (Lempa et al,
2000).
Two empirical arguments in favour of the 50-point positivity
criterion were found in the exploratory trial.
The first argument came from the negative extreme. If the worst
value in one dimension of the QoL profile (0 points) was obtained,
global QoL shifted dramatically down to values below 50 points.
Global QoL is a summary measure indicating necessity for taking
action (iatrotropy) (Wulff and Gotzsche, 2000).
The second argument came from the positive extreme and was
derived from sensitivity analysis: how much must QoL decrease in
any of nine single dimensions before global QoL as a summary
measure reacts with a decline below 50 points? Again, if at least
one specific QoL dimension decreased below 50 points then
also global QoL showed an effect (Figure 8). If any dimension of
QoL decreased to 0 the average value for global QoL fell below
50 points, even including interquartile range. In summary, this
relationship between global QoL and any other specific dimension
of QoL is in favour of selecting 50 points as a cutoff criterion for all
dimensions in the QoL profile (Koller et al, 2006).
CONCLUSION
A system of QoL diagnosis and therapy was successfully
implemented into routine patient care within a Tumor Center.
Patients’ responses and doctors’ judgements are necessary to
arrive at a full, clinically meaningful picture of patients’ well-being
and health status. A theoretically plausible and empirically proven
threshold level must be applied to distinguish between satisfactory
and critical levels of QoL in various dimensions.
After successful implementation, the QoL system is now ready
for exploration by definitive randomised controlled clinical trial
(Koller et al, 2006).
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